Patents by Inventor Uttam Saha
Uttam Saha has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11926583Abstract: A stabilized 1,25-dihydroxyvitamin D2 composition which is particularly well suited for pharmaceutical formulations, pharmaceutical formulations of the 1,25-dihydroxyvitamin D2 composition, and a method of making the purified composition by purifying a crude 1,25-dihydroxyvitamin D2 from acetone/water, are disclosed.Type: GrantFiled: January 2, 2014Date of Patent: March 12, 2024Assignee: EIRGEN PHARMA LTD.Inventor: Uttam Saha
-
Patent number: 11795148Abstract: Compounds that are inhibitors of retinoic acid inducible P450 (CYP26) enzymes. The compounds have retinoid activity, are resistant to CYP26-mediated catabolism, act as inhibitors of CYP26B1, and are used for treating diseases that are responsive to retinoids.Type: GrantFiled: December 12, 2018Date of Patent: October 24, 2023Assignee: Queen's University at KingstonInventors: Donald Andrew Cameron, Martin Petkovich, Uttam Saha
-
Patent number: 11358933Abstract: Compounds that are inhibitors of retinoic acid inducible P450 (CYP26) enzymes. The compounds have retinoid activity, are resistant to CYP26-mediated catabolism, act as inhibitors of CYP26B1, and are used for treating diseases that are responsive to retinoids.Type: GrantFiled: October 29, 2020Date of Patent: June 14, 2022Assignee: Queen's University at KingstonInventors: Donald Andrew Cameron, Martin Petkovich, Uttam Saha
-
Patent number: 11218137Abstract: The present disclosure relates to integrated circuits, and more particularly, to a low clock load dynamic dual output latch circuit and methods of operation. The structure includes: a plurality of dynamic clocked stacks which are configured to receive input data and provide a true logical value and a complement logical value; and a plurality of holding stacks which are configured to provide a hold signal to the dynamic clocked stacks and output the true logical value and the complement logical value in response to the hold signal being activated.Type: GrantFiled: April 14, 2020Date of Patent: January 4, 2022Assignee: GLOBALFOUNDRIES U.S. INC.Inventors: Uttam Saha, Mahbub Rashed
-
Publication number: 20210320650Abstract: The present disclosure relates to integrated circuits, and more particularly, to a low clock load dynamic dual output latch circuit and methods of operation. The structure includes: a plurality of dynamic clocked stacks which are configured to receive input data and provide a true logical value and a complement logical value; and a plurality of holding stacks which are configured to provide a hold signal to the dynamic clocked stacks and output the true logical value and the complement logical value in response to the hold signal being activated.Type: ApplicationFiled: April 14, 2020Publication date: October 14, 2021Inventors: Uttam SAHA, Mahbub RASHED
-
Patent number: 11050414Abstract: A dynamic single input-dual output latch includes input, feedback, and output stages. In the input stage, operations are dependent on a clock signal (CLK) and a feedback signal (FB) from the feedback stage. For example, when FB is at a low voltage level and CLK switches to a high voltage level, the input stage enters a data capture mode. Once data has been captured, FB switches back to the high voltage level, placing the input stage in a data hold mode. In the output stage, operations are dependent on CLK but independent of FB. For example, instead of initiating output signal stabilization only after both CLK and FB are at high voltage levels, weak pull-down transistors (including at least one CLK-controlled pull-down transistor) are employed in the output stage to ensure output signal stabilization is initiated after data capture has begun but before FB switches to the high voltage level.Type: GrantFiled: May 22, 2020Date of Patent: June 29, 2021Assignee: GLOBALFOUNDRIES U.S. Inc.Inventors: Uttam Saha, Mahbub Rashed
-
Publication number: 20210107870Abstract: Compounds that are inhibitors of retinoic acid inducible P450 (CYP26) enzymes. The compounds have retinoid activity, are resistant to CYP26-mediated catabolism, act as inhibitors of CYP26B1, and are used for treating diseases that are responsive to retinoids.Type: ApplicationFiled: October 29, 2020Publication date: April 15, 2021Inventors: Donald Andrew Cameron, Martin Petkovich, Uttam Saha
-
Publication number: 20200369609Abstract: Compounds that are inhibitors of retinoic acid inducible P450 (CYP26) enzymes. The compounds have retinoid activity, are resistant to CYP26-mediated catabolism, act as inhibitors of CYP26B1, and are used for treating diseases that are responsive to retinoids.Type: ApplicationFiled: December 12, 2018Publication date: November 26, 2020Inventors: Donald Andrew Cameron, Martin Petkovich, Uttam Saha
-
Publication number: 20190060456Abstract: This present disclosure is directed to novel prodrugs of activated vitamin D3 compounds. The prodrugs can be designed to have one or more beneficial properties, such as selective inhibition of the enzyme CYP24, low calcemic activity, and anti-proliferative activity. Specifically, these prodrugs are 1-deoxy prohormones of active Vitamin D analogs, e.g. analogs of calcitriol. This disclosure is also directed to pharmaceutical and diagnostic compositions containing the prodrugs of the invention, and to their medical use, particularly as prodrugs in the treatment and/or prevention of diseases.Type: ApplicationFiled: October 25, 2018Publication date: February 28, 2019Inventors: Gary H. Posner, Lindsey C. Hess, Alvin S. Kalinda, Rachel D. Slack, Uttam Saha, P. Martin Petkovich
-
Publication number: 20180117156Abstract: This present disclosure is directed to novel prodrugs of activated vitamin D3 compounds. The prodrugs can be designed to have one or more beneficial properties, such as selective inhibition of the enzyme CYP24, low calcemic activity, and anti-proliferative activity. Specifically, these prodrugs are 1-deoxy prohormones of active Vitamin D analogs, e.g. analogs of calcitriol. This disclosure is also directed to pharmaceutical and diagnostic compositions containing the prodrugs of the invention, and to their medical use, particularly as prodrugs in the treatment and/or prevention of diseases.Type: ApplicationFiled: October 2, 2017Publication date: May 3, 2018Inventors: Gary H. Posner, Lindsey C. Hess, Alvin S. Kalinda, Rachel D. Slack, Uttam Saha, P. Martin Petkovich
-
Patent number: 9775903Abstract: This present disclosure is directed to novel prodrugs of activated vitamin D3 compounds. The prodrugs can be designed to have one or more beneficial properties, such as selective inhibition of the enzyme CYP24, low calcemic activity, and anti-proliferative activity. Specifically, these prodrugs are 1-deoxy prohormones of active Vitamin D analogs, e.g. analogs of calcitriol. This disclosure is also directed to pharmaceutical and diagnostic compositions containing the prodrugs of the invention, and to their medical use, particularly as prodrugs in the treatment and/or prevention of diseases.Type: GrantFiled: January 13, 2011Date of Patent: October 3, 2017Assignees: JOHNS HOPKINS UNIVERSITY, OPKO IRELAND GLOBAL HOLDINGS, LTD.Inventors: Gary H. Posner, Lindsey C. Hess, Alvin S. Kalinda, Rachel D. Slack, Uttam Saha, P. Martin Petkovich
-
Patent number: 9198923Abstract: This invention relates to methods and small molecules having a phosphate group that can be used to inhibit phosphate transport and to treat or prevent diseases that are related to disorders in the maintenance of normal serum phosphate levels.Type: GrantFiled: January 26, 2010Date of Patent: December 1, 2015Assignee: OPKO IRELAND GLOBAL HOLDINGS, LTD.Inventors: Uttam Saha, Christian F. Helvig, P. Martin Petkovich
-
Patent number: 8906888Abstract: The present invention provides novel 16,23-diene 25-oxime ether analogs of 1,25-dihydroxy vitamin D3, compositions comprising these compounds and methods of using these compounds as inhibitors of CYP24. In particular, the novel compound of the invention are useful for treating diseases which benefit from a modulation of the levels of 1,25-dihydroxy vitamin D3, for example, cell-proliferative disorders.Type: GrantFiled: April 25, 2006Date of Patent: December 9, 2014Assignees: Cytochroma Inc., Johns Hopkins UniversityInventors: Uttam Saha, Gary H. Posner, Mehmet Kahraman
-
Publication number: 20140113886Abstract: A stabilized 1,25-dihydroxyvitamin D2 composition which is particularly well suited for pharmaceutical formulations, pharmaceutical formulations of the 1,25-dihydroxyvitamin D2 composition, and a method of making the purified composition by purifying a crude 1,25-dihydroxyvitamin D2 from acetone/water, are disclosed.Type: ApplicationFiled: January 2, 2014Publication date: April 24, 2014Applicant: CYTOCHROMA INC.Inventor: Uttam Saha
-
Publication number: 20130157987Abstract: This present disclosure is directed to novel prodrugs of activated vitamin D3 compounds. The prodrugs can be designed to have one or more beneficial properties, such as selective inhibition of the enzyme CYP24, low calcemic activity, and anti-proliferative activity. Specifically, these prodrugs are 1-deoxy prohormones of active Vitamin D analogs, e.g. analogs of calcitriol. This disclosure is also directed to pharmaceutical and diagnostic compositions containing the prodrugs of the invention, and to their medical use, particularly as prodrugs in the treatment and/or prevention of diseases.Type: ApplicationFiled: January 13, 2011Publication date: June 20, 2013Applicants: JOHNS HOPKINS UNIVERSITY, CYTOCHROMA INC.Inventors: Gary H. Posner, Lindsey C. Hess, Alvin S. Kalinda, Rachel D. Slack, Uttam Saha, P. Martin Petkovich
-
Publication number: 20120130133Abstract: Processes for preparing vitamin D2 derivatives and intermediates to vitamin D2 derivatives are disclosed. An improved photolysis process for the preparation of cis intermediate (I) from the trans starting material (II) are disclosed. Also disclosed is an improved process for the formation of a trans double bond at C22-C23 of the vitamin D2 derivative, which provides high selectivity of the desired trans double bond of compound (III) over the undesired cis double bond of compound (IIIA).Type: ApplicationFiled: November 25, 2009Publication date: May 24, 2012Applicant: CYTOCHROMA INC.Inventor: Uttam Saha
-
Publication number: 20120028926Abstract: This invention relates to methods and small molecules having a phosphate group that can be used to inhibit phosphate transport and to treat or prevent diseases that are related to disorders in the maintenance of normal serum phosphate levels.Type: ApplicationFiled: January 26, 2010Publication date: February 2, 2012Applicant: CYTOCHROMA INC.Inventors: Uttam Saha, Christian F. Helvig, P. Martin Petkovich
-
Patent number: 8106035Abstract: The present invention provides novel D-ring and side-chain analogs of 1?,25-dihydroxyvitamin D3, compositions comprising these compounds and methods of using these compounds as selective inhibitors of CYP24. In particular, the compounds of the invention are useful for treating diseases which benefit from a modulation of the levels of 1?,25-dihydroxyvitamin D3, for example, cell-proliferative disorders.Type: GrantFiled: December 18, 2003Date of Patent: January 31, 2012Assignee: Cytochroma Inc.Inventors: Gary H. Posner, Jae Kyoo Lee, Qiang Wang, Kenneth R. Crawford, Hong Woon Yang, Steven M. Silverman, Byung-Chul Suh, Jay A. White, Glenville Jones, Uttam Saha, Heung Bae Jeon
-
Patent number: 8039676Abstract: A process for producing a compound of the formula: including reacting of a compound of the formula: with diphenyl phosphine oxide using a binary phase reaction mixture including diphenyl phosphine oxide in an organic solvent, a basic aqueous solution, and a phase transfer catalyst, to obtain the compound of formula 1, wherein Ph is phenyl, X1 and X2 are both hydrogen or X1 and X2 taken together are CH2, R1 is a protecting group, R2 is fluorine, hydrogen, or OR3, wherein R3 is a protecting group, and the squiggly line represents a bond that results in the adjacent double bond being in either the E or Z configuration, is disclosed.Type: GrantFiled: May 29, 2008Date of Patent: October 18, 2011Assignee: Cytochroma Inc.Inventor: Uttam Saha
-
Patent number: 7973024Abstract: The present invention provides novel sulfoximine compounds, compositions comprising these compounds and methods of using these compounds as inhibitors of CYP24. In particular, the compounds of the invention are useful for treating diseases which benefit from a modulation of the levels of 1?,25-dihydroxy vitamin D3, for example, cell-proliferative disorders.Type: GrantFiled: May 30, 2006Date of Patent: July 5, 2011Assignee: Cyctochroma Inc.Inventors: Gary Posner, Mehmet Kahraman, Uttam Saha